80 related articles for article (PubMed ID: 15491616)
1. The dimeric and trimeric solution structures of the multidomain complement protein properdin by X-ray scattering, analytical ultracentrifugation and constrained modelling.
Sun Z; Reid KB; Perkins SJ
J Mol Biol; 2004 Nov; 343(5):1327-43. PubMed ID: 15491616
[TBL] [Abstract][Full Text] [Related]
2. Semi-rigid solution structures of heparin by constrained X-ray scattering modelling: new insight into heparin-protein complexes.
Khan S; Gor J; Mulloy B; Perkins SJ
J Mol Biol; 2010 Jan; 395(3):504-21. PubMed ID: 19895822
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System.
Pedersen DV; Gadeberg TAF; Thomas C; Wang Y; Joram N; Jensen RK; Mazarakis SMM; Revel M; El Sissy C; Petersen SV; Lindorff-Larsen K; Thiel S; Laursen NS; Fremeaux-Bacchi V; Andersen GR
Front Immunol; 2019; 10():2007. PubMed ID: 31507604
[TBL] [Abstract][Full Text] [Related]
4. The solution structure of the complement deregulator FHR5 reveals a compact dimer and provides new insights into CFHR5 nephropathy.
Kadkhodayi-Kholghi N; Bhatt JS; Gor J; McDermott LC; Gale DP; Perkins SJ
J Biol Chem; 2020 Nov; 295(48):16342-16358. PubMed ID: 32928961
[TBL] [Abstract][Full Text] [Related]
5. The solution structure of heparan sulfate differs from that of heparin: implications for function.
Khan S; Fung KW; Rodriguez E; Patel R; Gor J; Mulloy B; Perkins SJ
J Biol Chem; 2013 Sep; 288(39):27737-51. PubMed ID: 23921391
[TBL] [Abstract][Full Text] [Related]
6. The solution structures of two human IgG1 antibodies show conformational stability and accommodate their C1q and FcγR ligands.
Rayner LE; Hui GK; Gor J; Heenan RK; Dalby PA; Perkins SJ
J Biol Chem; 2015 Mar; 290(13):8420-38. PubMed ID: 25659433
[TBL] [Abstract][Full Text] [Related]
7. The Escherichia coli primosomal DnaT protein exists in solution as a monomer-trimer equilibrium system.
Szymanski MR; Jezewska MJ; Bujalowski W
Biochemistry; 2013 Mar; 52(11):1845-57. PubMed ID: 23418648
[TBL] [Abstract][Full Text] [Related]
8. Behavior of Tn3 resolvase in solution and its interaction with res.
Nöllmann M; Byron O; Stark WM
Biophys J; 2005 Sep; 89(3):1920-31. PubMed ID: 15980165
[TBL] [Abstract][Full Text] [Related]
9. Human Properdin Opsonizes Nanoparticles and Triggers a Potent Pro-inflammatory Response by Macrophages without Involving Complement Activation.
Kouser L; Paudyal B; Kaur A; Stenbeck G; Jones LA; Abozaid SM; Stover CM; Flahaut E; Sim RB; Kishore U
Front Immunol; 2018; 9():131. PubMed ID: 29483907
[TBL] [Abstract][Full Text] [Related]
10.
Wright DW; Perkins SJ
J Appl Crystallogr; 2015 Jun; 48(Pt 3):953-961. PubMed ID: 26089768
[TBL] [Abstract][Full Text] [Related]
11. Complement regulation at the molecular level: the structure of decay-accelerating factor.
Lukacik P; Roversi P; White J; Esser D; Smith GP; Billington J; Williams PA; Rudd PM; Wormald MR; Harvey DJ; Crispin MD; Radcliffe CM; Dwek RA; Evans DJ; Morgan BP; Smith RA; Lea SM
Proc Natl Acad Sci U S A; 2004 Feb; 101(5):1279-84. PubMed ID: 14734808
[TBL] [Abstract][Full Text] [Related]
12. Analysis of high-affinity assembly for AMPA receptor amino-terminal domains.
Zhao H; Berger AJ; Brown PH; Kumar J; Balbo A; May CA; Casillas E; Laue TM; Patterson GH; Mayer ML; Schuck P
J Gen Physiol; 2012 May; 139(5):371-88. PubMed ID: 22508847
[TBL] [Abstract][Full Text] [Related]
13. Crystallohydrodynamics of protein assemblies: Combining sedimentation, viscometry, and x-ray scattering.
Lu Y; Longman E; Davis KG; Ortega A; Grossmann JG; Michaelsen TE; de la Torre JG; Harding SE
Biophys J; 2006 Sep; 91(5):1688-97. PubMed ID: 16766619
[TBL] [Abstract][Full Text] [Related]
14. Extension of resolution and oligomerization-state studies of 2,4'-dihydroxyacetophenone dioxygenase from Alcaligenes sp. 4HAP.
Guo J; Erskine P; Coker AR; Gor J; Perkins SJ; Wood SP; Cooper JB
Acta Crystallogr F Struct Biol Commun; 2015 Oct; 71(Pt 10):1258-63. PubMed ID: 26457516
[TBL] [Abstract][Full Text] [Related]
15. Development of a novel representation of drug 3D structures and enhancement of the TSR-based method for probing drug and target interactions.
Milon TI; Wang Y; Fontenot RL; Khajouie P; Villinger F; Raghavan V; Xu W
Comput Biol Chem; 2024 Jun; 112():108117. PubMed ID: 38852360
[TBL] [Abstract][Full Text] [Related]
16. Characterization of mutant forms of recombinant human properdin lacking single thrombospondin type I repeats. Identification of modules important for function.
Higgins JM; Wiedemann H; Timpl R; Reid KB
J Immunol; 1995 Dec; 155(12):5777-85. PubMed ID: 7499866
[TBL] [Abstract][Full Text] [Related]
17. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
[TBL] [Abstract][Full Text] [Related]
18. The role of properdin in the assembly of the alternative pathway C3 convertases of complement.
Hourcade DE
J Biol Chem; 2006 Jan; 281(4):2128-32. PubMed ID: 16301317
[TBL] [Abstract][Full Text] [Related]
19. Native polymeric forms of properdin selectively bind to targets and promote activation of the alternative pathway of complement.
Ferreira VP; Cortes C; Pangburn MK
Immunobiology; 2010 Nov; 215(11):932-40. PubMed ID: 20382442
[TBL] [Abstract][Full Text] [Related]
20. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly.
Spitzer D; Mitchell LM; Atkinson JP; Hourcade DE
J Immunol; 2007 Aug; 179(4):2600-8. PubMed ID: 17675523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
